Restless legs syndrome (RLS) is a sleep-related movement disorder characterized by an irresistible urge to move the legs, often accompanied by uncomfortable sensations. Researchers have released new clinical guidelines for treating RLS, emphasizing patient-centered care and evidence-based updates.
The guidelines emphasize iron supplementation as a primary recommendation for addressing low brain iron in RLS patients. This approach has been shown to improve treatment outcomes for millions affected by RLS.
In contrast, dopamine agonists like pramipexole and ropinirole are now discouraged due to risks of worsening symptoms over time. Instead, new treatments such as alpha-2-delta ligands, nerve stimulation, and low-dose opioids gain conditional or strong recommendations.
The guidelines also stress the importance of addressing lifestyle factors, including caffeine and untreated sleep apnea, to optimize RLS management.
Key updates include:
* Iron supplementation is a primary recommendation for treating low brain iron in RLS patients.
* Dopamine agonists are now discouraged due to risks of symptom worsening over time.
* New treatments, including gabapentin and nerve stimulation, are supported for better efficacy and fewer side effects.
* Conditional recommendations against standard use of pramipexole and ropinirole have been added.
These updates reflect a decade of advancements in RLS treatment, aiming to improve outcomes for millions affected by the condition.
Source: https://neurosciencenews.com/restless-legs-syndrome-treatment-28044